The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 13, 2021
Filed:
Jun. 14, 2017
Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;
Universite Paris Diderot—paris 7, Paris, FR;
Assistance Publique-hopitaux DE Paris (Aphp), Paris, FR;
Universite DE Bordeaux, Bordeaux, FR;
Chu DE Bordeaux, Talence, FR;
Universite Paris Xiii Paris-nord, Villetaneuse, FR;
Eric Ogier-Denis, Paris, FR;
Xavier Treton, Paris, FR;
Yoram Bouhnik, Paris, FR;
Ian Morilla, Villetaneuse, FR;
David Laharie, Bordeaux, FR;
Gilles Wainrib, Paris, FR;
Mathieu Uzzan, Paris, FR;
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris, FR;
UNIVERSITE DE PARIS, Paris, FR;
ASSISTANCE PUBLIQUE-HOPPITAUX DE PARIS (APHP), Paris, FR;
UNIVERSITE DE BORDEAUX, Bordeaux, FR;
CHU DE BORDEAUX, Talence, FR;
UNIVERSITE PARIS XIII PARIS-NORD, Villetaneuse, FR;
Abstract
The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine. In particular, the present invention relates to methods for predicting acute severe colitis treatment response by measuring the expression levels of several miRNAs selected from the group consisting of hp_hsa-mir-3934, hp_hsa-mir-100, hsa-miR-718, hp_hsa-mir-193b, hsa-miR-3150a-5p, hp_hsa-mir-1260b, hsa-miR-938, hsa-miR-518b and hsa-miR-1468.